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A B S T R A C T
The distribution of pneumococcal serotypes among 465 invasive isolates recovered from 1999 to 2002 in
Portugal was analysed by age group. Serotype 14 was either the most prevalent or the second most
prevalent in all age groups. Among children aged < 2 years, serotypes 6B and 23F, which are usually
associated with children, together with serotypes 19A and 14, accounted for more than half of the
isolates. In contrast, in older adults (‡ 60 years), serotypes 3, 14, 1, 8 and 4 were the most prevalent. The
potential coverage of the seven-valent conjugate vaccine is 63.2% among infants, and does not change
significantly if children aged < 6 years are considered, which is a lower coverage than in other European
countries. The potential coverage of the 23-valent polysaccharide vaccine is high in all age groups,
particularly among older adults (80.7%). All isolates were tested for their susceptibility to penicillin,
cefuroxime, cefotaxime, vancomycin, erythromycin, clindamycin, levofloxacin, gatifloxacin, moxifloxa-
cin, linezolid, quinupristin–dalfopristin, tetracycline, chloramphenicol and trimethoprim–sulphameth-
oxazole. Most isolates collected from children aged < 6 years had decreased susceptibility to at least one
antibiotic class, whereas isolates from patients aged ‡ 6 years were mostly susceptible to all
antimicrobial agents tested. Overall, 23% of isolates showed reduced susceptibility to penicillin. Most
(98.5%) isolates remained fully susceptible to cefotaxime, and a single isolate was resistant to
quinolones.
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I N T R O D U C T I O N
Streptococcus pneumoniae is a major cause of
morbidity and mortality worldwide, causing
life-threatening infections such as meningitis,
pneumonia and febrile bacteraemia, but also less
severe and more common non-invasive manifes-
tations such as otitis media, sinusitis and recur-
rent bronchitis [1]. Pneumococcal infections are
most common among the very young, the elderly,
and people belonging to various risk groups
because of underlying illness [1]. The persistent
severity and frequency of S. pneumoniae infec-
tions, as well as the emergence of drug-resistant
S. pneumoniae isolates, have renewed the empha-
sis on prevention of pneumococcal disease.
A seven-valent conjugate vaccine was first
introduced in the USA at the beginning of 2000
[1] and is now licensed for use in several other
countries, including Portugal. The vaccine offers
protection against seven of the > 90 pneumococcal
capsular types, but only a few capsular types are
responsible for most infections in industrialised
countries [2]. Because of geographical variations in
serotype distribution, the vaccine may not be
universally optimal, and knowledge of pneumo-
coccal types is thus needed to evaluate the poten-
tial impact of vaccination in the population being
immunised.
The prevalence of drug-resistant S. pneumoniae
has increased worldwide, with regard not only
to penicillin, but also to other antimicrobials.
The emergence of multiresistant strains, and the
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temporal and geographical variations in resist-
ance patterns, suggest the need for continuous
monitoring [3].
This paper reports a survey of the serotype dis-
tribution of recent invasive pneumococcal isolates
in order to establish: (1) the potential coverage of
the seven-valent conjugated vaccine introduced in
June 2001 in Portugal; and (2) the susceptibility of
invasive pneumococcal isolates to various anti-
microbials, including the established treatment
choices for pneumococcal invasive infections, as
well as new antimicrobials soon to be made
available or introduced recently in Portugal.
M A T E R I A L S A N D M E T H O D S
Bacterial strains, species identification and serotyping
In total, 465 invasive S. pneumoniae isolates were collected
between 1999 and 2002 by 30 microbiology laboratories
throughout Portugal and sent to a central laboratory for
characterisation. During the 4-year period, 435 isolates (93.5%)
were recovered from blood, 18 (3.9%) from cerebrospinal
fluid, and 12 (2.6%) from other normally sterile fluids. Fifty-
seven (12%) were isolated from children aged < 2 years, and
171 (37%) from patients aged ‡ 60 years. All strains were
confirmed as S. pneumoniae by colonial morphology and
haemolysis on blood agar plates, optochin sensitivity and bile
solubility. Serotyping was performed by the standard capsular
reaction test with the chessboard system [4] and specific sera
(Statens Serum Institut, Copenhagen, Denmark).
Antibiotic susceptibility testing
Etest strips (AB Biodisk, Solna, Sweden) were used to
determine MICs according to the manufacturer’s instructions,
as described previously [5]. All strains were tested against
penicillin, cefuroxime, cefotaxime, erythromycin, clindamy-
cin, tetracycline, quinupristin–dalfopristin, linezolid,
levofloxacin, moxifloxacin and gatifloxacin. The breakpoints
recommended by the National Committee for Clinical Labor-
atory Standards [6] were used to interpret MIC values.
Isolates were characterised further by determining their
susceptibility to vancomycin, trimethoprim–sulphamethoxaz-
ole and chloramphenicol by the Kirby–Bauer disk diffusion
technique, again according to National Committee for Clin-
ical Laboratory Standards recommendations and interpretat-
ive criteria [6].
R E S U L T S
Distribution of serotypes
Table 1 shows the most common serotypes found
among the isolates from all age groups and
children aged < 6 years. The rank order and
serotypes accounting for c. 50% of the isolates
varied with the age group considered. In children
< 2 years of age, serotypes 14 (26.3%), 23F
(17.5%), 6B (8.8%) and 19A (8.8%) were the most
prevalent, while in individuals aged ‡ 60 years,
the prevalent serotypes were 3 (16.4%), 14
(13.5%), 1 (7%), 8 (6.4%) and 4 (5.3%).
Table 1. Serotypes of Streptococcus
pneumoniae isolates recovered from
patients with invasive disease from
1999 to 2002 in Portugal Serotype
Aged < 6 years
(n = 82)
Rank
Total (n ¼ 465)
Rankn % n %
14 21 25.6 1 62 13.3 1
1 10 12.2 3 50 10.8 2
3 3 3.7 6 45 9.7 3
4 0 0 – 27 5.8 4
8 0 0 – 27 5.8 4
9V 3 3.7 6 22 4.7 6
23F 14 17.1 2 22 4.7 6
7F 3 3.7 6 18 3.9 8
19A 5 6.1 5 17 3.7 9
12B 0 0 – 16 3.4 10
6B 8 9.8 4 14 3.0 11
6A 2 2.4 10 13 2.8 12
NT 0 0.0 – 13 2.8 12
18C 2 2.4 10 12 2.6 14
5 1 1.2 13 12 2.6 14
22F 0 0 – 11 2.4 16
9N 1 1.2 13 10 2.2 17
19F 1 1.2 13 9 1.9 18
10A 2 2.4 10 9 1.9 18
11A 0 0 – 7 1.5 20
33F 3 3.7 6 6 1.3 21
20 0 0 – 5 1.1 22
18A 0 0 – 5 1.1 22
Othera 3 3.6 – 33 6.1 –
aIsolates in this category reacted only with one of the pools C, D, G, H or I of the chessboard system [4] and were not
characterised further, or belonged to serotypes represented by fewer than five isolates. The distribution of isolates
typed was as follows: a single isolate of type 15B recovered from a child aged < 6 years; three isolates of type 10F,
two isolates each of types 15B, 17 and 23B, and a single isolate each of types 23A, 7B, 33A and 11.
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The serotype coverage rates of pneumococcal
vaccines for four different age groups are indica-
ted in Table 2, including the potential coverage of
the 23-valent polysaccharide vaccine in young
children (for which it is not indicated). The
potential coverage of the conjugate vaccines was
calculated to include type 6A isolates, since it has
been shown that antibodies against type 6B offer
cross-protection to type 6A [7]. Non-vaccine types
constituted 19.4% of all invasive infections.
Antimicrobial susceptibility
Most isolates collected from children aged
6 months to 6 years had decreased susceptibility
to at least one antibiotic class (63.8%), whereas
isolates obtained from patients aged ‡ 6 years
were mostly (70.7%) susceptible to all antimicro-
bial agents tested. Table 3 summarises the MIC
ranges, and MIC50 and MIC90 values, for all
antibiotics tested. Overall, 22.9% (n ¼ 107) of
isolates were resistant to penicillin, of which
18.2% had low-level resistance, and 4.7% had
high-level resistance. The frequency of high-level
resistance to penicillin was similar in all age
groups. Resistance to third-generation cephalo-
sporins (cefotaxime) was very low (1.5%), and no
resistance was observed to linezolid and vanco-
mycin. Only one strain, isolated from an adult,
showed resistance to the fluoroquinolones (i.e.,
levofloxacin, moxifloxacin and gatifloxacin). Four
isolates showed low-level resistance to quinupr-
istin–dalfopristin. Most macrolide-resistant iso-
lates (n ¼ 44) showed the MLSB phenotype (77%),
while the remaining isolates showed the M
phenotype. Resistance to either chloramphenicol
(3%) or tetracycline (7%) was low, whereas 22%
of the isolates were resistant to trimethoprim–
sulphamethoxazole. Resistance to individual anti-
microbial agents other than penicillin was found
in 13 (15.9%) isolates from children aged
< 6 years, and in 41 (10.8%) isolates recovered
from patients aged ‡ 6 years.
D I S C U S S I O N
The data presented indicated that the potential
coverage of the currently available seven-valent
conjugate vaccine in Portugal among children
aged < 2 years, for whom it is currently recom-
mended [1], is 63.2% (Table 2). This is a lower
value than the 70–80% coverage reported in other
European countries [8–11]. It is interesting to note
that the expected seven-valent vaccine coverage
does not change significantly if children aged
< 6 years are considered. The importance of this
finding relates to current recommendations sug-
gesting vaccination of children aged £ 5 years
who attend day care centres [1], as most children
in Portugal in this age group are in this category.
Prevention of pneumococcal invasive disease
among children in Portugal could benefit greatly
from the availability of higher-valence conjugate
Table 2. Potential vaccine coverage based on Streptococcus
pneumoniae isolates recovered from patients with invasive
disease from 1999 to 2002 in Portugal
Vaccines
Age group
< 2 years
(n = 57)
‡ 2–6 years
(n = 25)
‡ 6–60 years
(n = 212)
‡ 60 years
(n = 171)
Seven-valent 63.2% 60.0% 33.0% 35.1%
Nine-valent 68.4% 92.0% 50.0% 43.9%
11-valent 77.2% 96.0% 60.8% 63.7%
23-valent 86.0% 100.0% 76.9% 80.7%
Table 3. Antimicrobial susceptibility of 465 Streptococcus pneumoniae isolates recovered from patients with invasive disease
from 1999 to 2002 in Portugal
Antibiotic
Aged < 6 years (n = 82) Total isolates (n ¼ 465)
MIC range
(mg ⁄L)
MIC50
(mg ⁄L)
MIC90
(mg ⁄L) n R%a
MIC range
(mg ⁄L)
MIC50
(mg ⁄L)
MIC90
(mg ⁄L) n R%a
Penicillin 0.008–3 0.032 1.5 36 43.9 0.006–4 0.023 1 107 23.0
Cefuroxime < 0.016–6 0.047 1.5 24 29.3 < 0.016–12 0.023 1.5 78 16.8
Cefotaxime 0.006–4 0.023 0.5 1 1.2 0.006–4 0.016 0.38 7 1.5
Erythromycin 0.016– > 256 0.064 > 256 17 20.7 0.016– > 256 0.047 0.125 44 9.5
Clindamycin 0.032– > 256 0.094 > 256 13 15.9 0.023– > 256 0.094 0.19 38 8.2
Levofloxacin 0.19–1 0.5 0.75 0 0 0.032–12 0.5 0.75 1 0.2
Gatifloxacin 0.094–0.25 0.19 0.25 0 0 0.023–2 0.19 0.25 1 0.2
Moxifloxacin 0.047–0.19 0.094 0.125 0 0 0.023–1.5 0.094 0.125 1 0.2
Linezolid 0.125–1 0.5 1 0 0 0.064–1 0.5 0.75 0 0
Quinupristin–dalfopristin 0.38–1 0.75 0.75 0 0 0.38–1.5 0.5 0.75 4 0.9
aResistance defined as isolates with either intermediate or high-level resistance [6].
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vaccines, since coverage of the nine-valent vac-
cine among children aged < 6 years is 75.6%,
increasing to 82.9% with the 11-valent vaccine.
These observations are in contrast with recent
reports from other European countries, where the
potential gains from higher-valence vaccines are
not so pronounced [9,10]. However, these values
may underestimate the impact of vaccination,
since a recent report suggests that vaccination
may provide protection against invasive disease
by all serotypes of the serogroups included in the
vaccine [12].
In line with other European reports, the poten-
tial coverage of the 23-valent polysaccharide
vaccine is high (80.7%) among individuals aged
‡ 60 years and for all other age groups considered
(Table 2), although the efficacy of this vaccine in
preventing pneumococcal disease seems to be
restricted to bacteraemic manifestations [13].
Most isolates collected from children aged
< 6 years had decreased susceptibility to at least
one antibiotic class, in contrast to isolates
obtained from patients aged ‡ 6 years, which
were mostly susceptible to all antimicrobials
tested. The percentage of resistant isolates was
also higher in children aged < 6 years compared
to older individuals (Table 3) (one-tailed chi-
square test, p < 0.002), possibly because of higher
antimicrobial consumption [14].
In children aged < 6 years, all four isolates with
high-level penicillin resistance were of serotype
14, and were also multiresistant (resistant to three
or more antimicrobial classes). In contrast, low-
level resistance was found in seven different
serotypes (14, 23F, 6B, 9V, 19A, 19F and 15B),
and a high proportion (62.5%) of these were
multiresistant. Since the seven-valent conjugate
vaccine covers most of these serotypes, its use
could have the added benefit of reducing the
impact of penicillin-resistant strains on invasive
disease. These same serotypes are associated with
internationally disseminated clones, and have
been associated already with decreased suscept-
ibility to penicillin among carriage isolates in the
same age group in Portugal [15]. Of 71 isolates
with reduced susceptibility to penicillin collected
from people aged > 6 years, the 18 high-level
resistant isolates were concentrated in serotypes
14, 9V and 19A and were multiresistant. Strains
with low-level resistance belonged to 12 different
serotypes, but most (n ¼ 40) were also multire-
sistant. However, despite a high frequency of
penicillin non-susceptibility, S. pneumoniae iso-
lates in Portugal remained largely susceptible
(98.5%) to cefotaxime in vitro, which continues to
be a safe choice for empirical treatment of inva-
sive infections in Portugal. This is in contrast to
the situation in Spain, where resistance to
cefotaxime has been reported to be 13% [16].
Resistance to the quinolones and quinupristin–
dalfopristin was < 1%.
Overall, the data presented in this paper high-
light the importance of national surveys to evalu-
ate the potential benefits of pneumococcal
vaccination, and suggest that the impact of the
seven-valent vaccine on invasive disease in Por-
tugal may not be as high as in other countries in
Europe, including the neighbouring country of
Spain [8–11].
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